the development and results of a dose-intense regimen using 177lu-psma-617 for progressive mcrpc
Published 3 months ago • 54 plays • Length 2:02Download video MP4
Download video MP3
Similar videos
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
0:29
a phase i/ii dose-escalation study of fractionated dose 177lu-psma-617 for progressive mcrpc
-
3:01
preliminary findings in mcrpc for fractionated dose 177lu-psma-617
-
5:45
efficacy and toxicity of 177lu-psma-617 for mcrpc in a real-world setting
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
10:20
psmafore results: [177lu]lu-psma-617 in taxane-naive patients with mcrpc
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
1:13:59
prostic24- mdt psma pet
-
8:15
how pet scans see cancer
-
26:28
advances in non-metastatic prostate cancer: navigating arpis and precision diagnostics
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
3:25
highlights on lu-psma-617 in taxane-naive patients with mcrpc: the psmafore study
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
1:09
psma imaging pre- and post-177lu-psma-617 treatment in mcrpc
-
1:06
the benefits of 177lu-psma-617 plus olaparib for prostate cancer
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
1:48
expert discusses fractionated dose 177lu-psma-617 in mcrpc
-
3:17
safety and efficacy of 177lu-psma-617
-
11:39
psmafore trial & enzalutamide with 177lu-psma-617 for mcrpc | dr. dharmender malik | 05th knowledge